Zhang Guojun, Sun Xudong, Lv Hong, Yang Xiaolin, Kang Xixiong
Laboratory Diagnosis Center, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing 100050, P.R. China.
Oncol Lett. 2012 Apr 1;3(4):940-944. doi: 10.3892/ol.2012.584. Epub 2012 Jan 30.
Previous studies reported that serum amyloid A (SAA) is elevated in patients with tumors, including breast cancer, compared to healthy controls. In addition, the levels of SAA increase gradually with tumor progression. In this study, we investigated the blood SAA level of breast cancer patients, and evaluated its potential as a serum biomarker for the early diagnosis of breast cancer and as a staging estimate. SAA protein was determined by enzyme-linked immunosorbent assay in serum samples from 30 healthy women, 21 women with benign diseases and 118 breast cancer patients who were subdivided into 4 groups based on their clinical characteristics. SAA levels were not statistically different in stage I breast cancer patients compared with the healthy controls and benign breast disease patients. SAA concentrations had medians of 0.63 µg/ml in normal healthy women, 0.76 µg/ml in patients with benign disease (p>0.05) and 0.82 µg/ml in stage I breast cancer patients (p>0.05). By contrast, SAA values in stage Ⅱ, Ⅲ and Ⅳ patients had a significantly higher median compared to those of the healthy, benign breast diseases and stage I groups (p<0.05). Breast cancer patients with lymph node (LN) metastasis or distant metastasis were found to have significantly higher SAA concentrations than those without metastases. SAA is not a suitable marker for early breast cancer diagnosis, but its level is correlated with the stage of breast cancer. Thus, it may be a good candidate marker for the staging and prognosis of breast cancer.
以往研究报道，与健康对照相比，包括乳腺癌在内的肿瘤患者血清淀粉样蛋白A（SAA）水平升高。此外，SAA水平随肿瘤进展而逐渐升高。在本研究中，我们调查了乳腺癌患者的血液SAA水平，并评估了其作为乳腺癌早期诊断血清生物标志物和分期评估指标的潜力。通过酶联免疫吸附测定法测定了30名健康女性、21名患有良性疾病的女性以及118名乳腺癌患者血清样本中的SAA蛋白，这些乳腺癌患者根据临床特征被分为4组。与健康对照和良性乳腺疾病患者相比，I期乳腺癌患者的SAA水平无统计学差异。正常健康女性的SAA浓度中位数为0.63µg/ml，良性疾病患者为0.76µg/ml（p>0.05），I期乳腺癌患者为0.82µg/ml（p>0.05）。相比之下，II期、III期和IV期患者的SAA值中位数显著高于健康、良性乳腺疾病和I期组（p<0.05）。发现有淋巴结（LN）转移或远处转移的乳腺癌患者的SAA浓度显著高于无转移患者。SAA不是早期乳腺癌诊断的合适标志物，但其水平与乳腺癌分期相关。因此，它可能是乳腺癌分期和预后的良好候选标志物。
